AZD9150 + durvalumab + cisplatin + 5-fluorouracil

This is a combination regimen consisting of four drugs: - **AZD9150 (danvatirsen):** An antisense oligonucleotide inhibitor of the transcription factor STAT3, developed as a targeted therapy for cancer. AZD9150 reduces STAT3 expression, a factor involved in cancer cell growth and immune evasion[2][4]. - **Durvalumab (MEDI4736, Imfinzi):** A monoclonal antibody that targets programmed death-ligand 1 (PD-L1), acting as a checkpoint inhibitor to restore antitumor immune response. - **Cisplatin:** A platinum-based chemotherapeutic agent that induces DNA cross-linking and apoptosis in rapidly dividing tumor cells. - **5-Fluorouracil:** A pyrimidine analog antimetabolite, used to disrupt DNA synthesis by inhibiting thymidylate synthase, leading to cytotoxicity in proliferating cells. This multi-agent regimen is being evaluated in advanced solid malignancies, including head and neck squamous cell carcinoma, to combine targeted inhibition (STAT3), immune checkpoint blockade (PD-L1), and cytotoxic chemotherapy for potential synergistic antitumor effects[1].

Other names

danvatirsenMEDI4736MEDI-4736MEDI 4736cisplatin5-fluorouracil